The Law of Compounding Medications And Drugs: Fierce Pharma Manufacturing Top Stories: Look at Manufacturing plant closings and job cuts. Are we beginning to see the end of Big pharma medications (commercially available FDA-approved drugs) and a shift to complete compounded medications? Is this a cause and effect of allowing to many unregulated, untested, unapproved drugs in the market? What happens if big pharma can no longer afford to produce FDA-approved medications in the current market?

Thursday, December 11, 2014

Fierce Pharma Manufacturing Top Stories: Look at Manufacturing plant closings and job cuts. Are we beginning to see the end of Big pharma medications (commercially available FDA-approved drugs) and a shift to complete compounded medications? Is this a cause and effect of allowing to many unregulated, untested, unapproved drugs in the market? What happens if big pharma can no longer afford to produce FDA-approved medications in the current market?

Today's Top Stories
1. AstraZeneca closing U.S. plant, costing 180 jobs
2. More Novartis jobs cut in New York as plant suffers drawn-out drawdown
3. Romark building $110M plant in Puerto Rico
4. Indonesia's Indofarma and Kimia combine manufacturing, supply chain strengths
5. Indian drugmakers lambast proposed PET packaging

No comments:

Subscribe to: Post Comments (Atom)